PMID- 31818689
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201015
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 30
IP  - 1
DP  - 2020 Jan
TI  - [Is sarcopenia a morbi-mortality factor in the treatment of localized 
      muscle-invasive bladder cancer?].
PG  - 41-50
LID - S1166-7087(19)30610-4 [pii]
LID - 10.1016/j.purol.2019.11.002 [doi]
AB  - INTRODUCTION: Sarcopenia evaluated from the measurement of skeletal muscle index 
      (SMI) has been evaluated as a predictive factor of morbidity and mortality after 
      surgery. The objective of this study was to evaluate whether it was predictive of 
      morbidity and mortality in patients managed by cystectomy or tri-modality therapy 
      (TMT), combining radiotherapy and chemotherapy after endoscopic resection of the 
      tumour, for localized muscle-invasive bladder cancer. MATERIALS AND METHODS: In 
      all, 146 consecutive patients from 2 university hospital centres treated by 
      cystectomy between January 2012 and April 2017 or TMT between October 2008 and 
      October 2014 were included. The SMI was measured on axial computed-tomography at 
      the level of the transverse process of L3, before treatment. Sarcopenia was 
      assessed in two ways: either by SMI without muscle mass adjustment or according 
      to the definition by Martin and al. based on gender and patient BMI, then called 
      "adjusted sarcopenia". The primary endpoint was overall survival (OS) for 
      sarcopenia. The secondary endpoints were OS, progression-free survival (PFS) and 
      survival without re-admission (SRH) for the total population and for each 
      treatment group. Survival analyses were performed using the Cox model. The 
      association between sarcopenia and complications has been investigated by the 
      Chi(2) test. RESULTS: The characteristics of sarcopenic (n=67) and non-sarcopenic 
      (n=79) patients were comparable except for 2 criteria: older patients in the 
      sarcopenic group and a higher proportion of neo-adjuvant chemotherapy in 
      non-sarcopenic patients. Sarcopenia was not significantly associated with any 
      type of survival. Sarcopenia was not associated with the proportion or severity 
      of complications. CONCLUSION: Unlike unadjusted SMI, sarcopenia was not 
      associated with survival or complications. LEVEL OF EVIDENCE: 3.
CI  - Copyright (c) 2019 Elsevier Masson SAS. All rights reserved.
FAU - Fraisse, G
AU  - Fraisse G
AD  - Service d'urologie, CHU Bicetre, 94270 Le Kremlin-Bicetre, France. Electronic 
      address: fraisse_guillaume@hotmail.com.
FAU - Renard, Y
AU  - Renard Y
AD  - Service de chirurgie digestive, CHU de Reims, 51100 Reims, France.
FAU - Lebacle, C
AU  - Lebacle C
AD  - Service d'urologie, CHU Bicetre, 94270 Le Kremlin-Bicetre, France.
FAU - Masson-Lecomte, A
AU  - Masson-Lecomte A
AD  - Service d'urologie, CHU Saint Louis, 75010 Paris, France.
FAU - Desgrandchamps, F
AU  - Desgrandchamps F
AD  - Service d'urologie, CHU Saint Louis, 75010 Paris, France.
FAU - Hennequin, C
AU  - Hennequin C
AD  - Service de radiotherapie, CHU Saint Louis, 75010 Paris, France.
FAU - Bessede, T
AU  - Bessede T
AD  - Service d'urologie, CHU Bicetre, 94270 Le Kremlin-Bicetre, France.
FAU - Irani, J
AU  - Irani J
AD  - Service d'urologie, CHU Bicetre, 94270 Le Kremlin-Bicetre, France.
LA  - fre
PT  - Journal Article
PT  - Multicenter Study
TT  - La sarcopenie est-elle un facteur de morbi-mortalite dans le traitement des 
      tumeurs localisees de la vessie infiltrant le muscle ?
DEP - 20191206
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
SB  - IM
MH  - Aged
MH  - Combined Modality Therapy
MH  - Cystectomy/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoadjuvant Therapy/methods
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Sarcopenia/*etiology
MH  - Survival Rate
MH  - Tomography, X-Ray Computed
MH  - Urinary Bladder Neoplasms/pathology/*therapy
OTO - NOTNLM
OT  - Cancer de la vessie
OT  - Cystectomie
OT  - Cystectomy
OT  - Localized muscle-invasive bladder cancer
OT  - Sarcopenia
OT  - Sarcopenie
OT  - Traitement tri-modal
OT  - Tri-modality therapy
OT  - Tumeur de la vessie infiltrant le muscle
EDAT- 2019/12/11 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/12/11 06:00
PHST- 2019/07/22 00:00 [received]
PHST- 2019/10/14 00:00 [revised]
PHST- 2019/11/07 00:00 [accepted]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/12/11 06:00 [entrez]
AID - S1166-7087(19)30610-4 [pii]
AID - 10.1016/j.purol.2019.11.002 [doi]
PST - ppublish
SO  - Prog Urol. 2020 Jan;30(1):41-50. doi: 10.1016/j.purol.2019.11.002. Epub 2019 Dec 
      6.